Epirium is a clinical stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel and clinically significant therapeutic approaches to currently intractable neuromuscular diseases. The Company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/19 | $85,000,000 | Series A |
Adams Street Partners ARCH Venture Partners Bluebird Ventures Longitude Capital The Longevity Fund Vertex Venture Holdings | undisclosed |
